The WIP1 Oncogene Promotes Progression and Invasion of Aggressive Medulloblastoma Variants

Recent studies suggest that medulloblastoma, the most common malignant brain tumor of childhood, is comprised of four disease variants. The WIP1 oncogene is overexpressed in Group 3 and 4 tumors, which contain medulloblastomas with the most aggressive clinical behavior. Our data demonstrate increased WIP1 expression in metastatic medulloblastomas, and inferior progression-free and overall survival of patients with WIP1 high-expressing medulloblastoma. Microarray analysis identified upregulation of genes involved in tumor metastasis, including the G protein-coupled receptor CXCR4, in medulloblastoma cells with high WIP1 expression. Stimulation with the CXCR4 ligand SDF1α activated PI-3 kinase signaling, and promoted growth and invasion of WIP1 high-expressing medulloblastoma cells in a p53-dependent manner. When xenografted into the cerebellum of immunodeficient mice, medulloblastoma cells with stable or endogenous high WIP1 expression exhibited strong expression of CXCR4 and activated AKT in primary and invasive tumor cells. WIP1 or CXCR4 knockdown inhibited medulloblastoma growth and invasion. WIP1 knockdown also improved the survival of mice xenografted with WIP1 high-expressing medulloblastoma cells. WIP1 knockdown inhibited cell surface localization of CXCR4 by suppressing expression of the G protein receptor kinase 5, GRK5. Restoration of wild-type GRK5 promoted Ser339 phosphorylation of CXCR4 and inhibited the growth of WIP1-stable medulloblastoma cells. Conversely, GRK5 knockdown inhibited Ser339 phosphorylation of CXCR4, increased cell surface localization of CXCR4 and promoted the growth of medulloblastoma cells with low WIP1 expression. These results demonstrate crosstalk among WIP1, CXCR4 and GRK5, which may be important for the aggressive phenotype of a subclass of medulloblastomas in children.

[1]  Jill P. Mesirov,et al.  MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.

[2]  G. Reifenberger,et al.  Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. , 2010, Cancer research.

[3]  D. Ellison,et al.  Wnt/Wingless Pathway Activation and Chromosome 6 Loss Characterise a Distinct Molecular Sub-Group of Medulloblastomas Associated with a Favourable Prognosis , 2006, Cell cycle.

[4]  L. Donehower,et al.  PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. , 2005, Genes & development.

[5]  M. Protopopova,et al.  Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.

[6]  L. Donehower,et al.  Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice , 2006, Molecular carcinogenesis.

[7]  K. Lindsley Surveillance scanning of children with medulloblastoma. , 1994, The New England journal of medicine.

[8]  S. Scherer,et al.  Clonal Selection Drives Genetic Divergence of Metastatic Medulloblastoma , 2012, Nature.

[9]  Hendrik Witt,et al.  Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Pietsch,et al.  p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease , 2011, Journal of Neuro-Oncology.

[11]  N. Onishi,et al.  Intrinsic Kinase Activity and SQ/TQ Domain of Chk2 Kinase as Well as N-terminal Domain of Wip1 Phosphatase Are Required for Regulation of Chk2 by Wip1* , 2006, Journal of Biological Chemistry.

[12]  E. Appella,et al.  Genetic variants and mutations of PPM1D control the response to DNA damage , 2013, Cell cycle.

[13]  E. Appella,et al.  The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis , 2007, Oncogene.

[14]  Axel Benner,et al.  Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  B. Hinkes,et al.  Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. , 2009, European journal of cancer.

[16]  Yi Sun,et al.  Targeting p53 for Novel Anticancer Therapy. , 2010, Translational oncology.

[17]  Shaomeng Wang,et al.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.

[18]  S. Croul,et al.  Adult medulloblastoma comprises three major molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Curran,et al.  A phase I pharmacokinetic trial of sonic hedgehog (SHH) antagonist GDC-0449 in pediatric patients with recurrent or refractory medulloblastoma: A Pediatric Brain Tumor Consortium study (PBTC 25). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Fiscella,et al.  Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Peter Donnelly,et al.  Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer , 2012, Nature.

[22]  E. Appella,et al.  Wip1 phosphatase regulates p53-dependent apoptosis of stem cells and tumorigenesis in the mouse intestine. , 2007, Cell stem cell.

[23]  J. Gutkind,et al.  G-protein-coupled receptors and cancer , 2007, Nature Reviews Cancer.

[24]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.

[25]  E. Appella,et al.  Wip1 phosphatase modulates ATM-dependent signaling pathways. , 2006, Molecular cell.

[26]  N. Onishi,et al.  Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase , 2006, Cell Death and Differentiation.

[27]  S. Donaldson,et al.  Medulloblastoma: freedom from relapse longer than 8 years--a therapeutic cure? , 1991, Journal of neurosurgery.

[28]  J. Benovic,et al.  G protein-coupled receptor kinase 5 phosphorylation of hip regulates internalization of the chemokine receptor CXCR4. , 2011, Biochemistry.

[29]  P. Northcott,et al.  Functional genomics identifies drivers of medulloblastoma dissemination. , 2012, Cancer research.

[30]  S. Pfister Medulloblastoma: a potpourri of distinct entities , 2012, Acta Neuropathologica.

[31]  C. Rudin,et al.  Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma , 2009, Science.

[32]  M. Scott,et al.  Altered neural cell fates and medulloblastoma in mouse patched mutants. , 1997, Science.

[33]  T. Merchant,et al.  Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.

[34]  E. D. de Vries,et al.  A review on CXCR4/CXCL12 axis in oncology: no place to hide. , 2013, European journal of cancer.

[35]  D. Ellison,et al.  Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients , 2004, Clinical Cancer Research.

[36]  Roger E. Taylor,et al.  Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[38]  S. Mundell,et al.  Trafficking of the HIV Coreceptor CXCR4 , 1999, The Journal of Biological Chemistry.

[39]  Masaaki Adachi,et al.  p53‐inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK‐p53 signaling in response to UV radiation , 2000, The EMBO journal.

[40]  Axel Benner,et al.  Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Axel Benner,et al.  FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Xiongbin Lu,et al.  The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. , 2007, Cancer cell.

[43]  P. Northcott,et al.  CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma. , 2012, Cancer research.

[44]  Jeffrey R. Marks,et al.  Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23 , 2002, Nature Genetics.

[45]  Albert J. Fornace,et al.  Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity , 2002, Nature Genetics.

[46]  L. Clegg,et al.  Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results. , 2002, Medical and pediatric oncology.

[47]  K. Gandhi,et al.  HDM2 promotes WIP1-mediated medulloblastoma growth. , 2012, Neuro-oncology.

[48]  J. Benovic,et al.  The role of receptor kinases and arrestins in G protein-coupled receptor regulation. , 1998, Annual review of pharmacology and toxicology.

[49]  Lawrence A. Donehower,et al.  Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D , 2007, Journal of Neuro-Oncology.

[50]  Arie Perry,et al.  Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups , 2011, Acta Neuropathologica.

[51]  J. Bartek,et al.  Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint , 2013, The Journal of cell biology.

[52]  L. Borgognoni,et al.  WIP1 phosphatase modulates the Hedgehog signaling by enhancing GLI1 function , 2013, Oncogene.

[53]  G. Rao,et al.  c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice. , 2003, Neoplasia.

[54]  Andrew L Kung,et al.  A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Mark L. Greenberg,et al.  Serial evaluation of academic and behavioral outcome after treatment with cranial radiation in childhood. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  C. Marras,et al.  Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas , 2006, Cancer biology & therapy.

[57]  Akira Nakagawara,et al.  PPM1D is a potential target for 17q gain in neuroblastoma. , 2003, Cancer research.

[58]  J. Biegel,et al.  Isochromosome 17q Is a Negative Prognostic Factor in Poor-Risk Childhood Medulloblastoma Patients , 2005, Clinical Cancer Research.

[59]  N. Warrington,et al.  Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. , 2005, Cancer research.

[60]  R. Klein,et al.  SDF-1 alpha induces chemotaxis and enhances Sonic hedgehog-induced proliferation of cerebellar granule cells. , 2001, Development.

[61]  J. Mesirov,et al.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Steven J. M. Jones,et al.  Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.

[63]  Dirk Troost,et al.  Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.

[64]  X. Bian,et al.  PREFERENTIAL EXPRESSION OF CHEMOKINE RECEPTOR CXCR4 BY HIGHLY MALIGNANT HUMAN GLIOMAS AND ITS ASSOCIATION WITH POOR PATIENT SURVIVAL , 2007, Neurosurgery.

[65]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[66]  X. Bian,et al.  Preferential Expression of Chemokine Receptor CXCR4 by Highly Malignant Human Gliomas and Its Association with Poor Patient Survival. , 2008, Neurosurgery.

[67]  John Y. H. Kim,et al.  Overexpressed TP73 induces apoptosis in medulloblastoma , 2007, BMC Cancer.

[68]  G. Riggins,et al.  c-Myc promoter activation in medulloblastoma. , 2003, Cancer research.